Insider · CIK 0001276700

KARBE FRANK

Reports to the SEC for 7 companies · FLORHAM PARK, NJ

sec.gov

Transactions

Companies

Filings

CIK

0001276700

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-05-19	PHATPhathom Pharmaceuticals, Inc.A Award	Director	AAward	+24.1K sh	—	—	91,622
2026-01-07	CDTXCidara Therapeutics, Inc. · Employee Stock Option (right to buy)D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−115K sh	—	—	0
2026-01-07	CDTXCidara Therapeutics, Inc.D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−7,526 sh	$221.50	−$1.67M	43,125
2026-01-07	CDTXCidara Therapeutics, Inc.D Disposition to Issuer	Chief Financial Officer	DDisposition to Issuer	−43.1K sh	—	—	0
2025-12-10	CDTXCidara Therapeutics, Inc.F Tax Payment	Chief Financial Officer	FTax Payment	−7,290 sh	$219.60	−$1.6M	50,562
2025-06-03	PHATPhathom Pharmaceuticals, Inc.A Award	Director	AAward	+10.5K sh	—	—	67,500
2025-06-03	PHATPhathom Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+17.5K sh	—	—	17,500
2025-02-24	CDTXCidara Therapeutics, Inc. · Employee Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+115K sh	—	—	115,000
2025-02-24	CDTXCidara Therapeutics, Inc.A Award	Chief Financial Officer	AAward	+57.5K sh	—	—	57,500
2024-12-13	PHATPhathom Pharmaceuticals, Inc.P Purchase	Director	PPurchase	+12.5K sh	$7.93	+$99.1K	57,000
2024-05-29	PHATPhathom Pharmaceuticals, Inc.A Award	Director	AAward	+25K sh	$10.16	+$254K	44,500
2024-05-23	PHATPhathom Pharmaceuticals, Inc.A Award	Director	AAward	+10.5K sh	—	—	19,500
2024-05-23	PHATPhathom Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	−17.5K sh	—	—	17,500
2023-12-18	Better Therapeutics, Inc.A Award	Director, Chief Executive Officer	AAward	+62.5K sh	—	—	526,516
2023-07-27	Better Therapeutics, Inc.P Purchase	Director, Chief Executive Officer	PPurchase	+137K sh	$0.73	+$100K	429,429
2023-05-25	PHATPhathom Pharmaceuticals, Inc.A Award	Director	AAward	+9,000 sh	—	—	9,000
2023-05-25	PHATPhathom Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+15K sh	—	—	15,000
2023-04-10	Better Therapeutics, Inc.P Purchase	Director, Chief Executive Officer	PPurchase	+242K sh	$0.82	+$200K	292,424
2022-09-15	Better Therapeutics, Inc.P Purchase	Director, Chief Executive Officer	PPurchase	+50K sh	$2.09	+$105K	50,000
2022-07-05	Better Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director, Chief Executive Officer	AAward	+472K sh	—	—	472,200
2022-05-25	PHATPhathom Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+10K sh	—	—	10,000
2022-04-25	PHATPhathom Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+20K sh	—	—	20,000
2021-07-07	Myovant Sciences Ltd.S Sale	Principal Fin'l & Accounting	SSale	−3,232 sh	$21.75	−$70.3K	212,296
2021-04-15	Myovant Sciences Ltd.A Award	Principal Fin'l & Accounting	AAward	+63.1K sh	—	—	215,528
2021-04-15	Myovant Sciences Ltd.Stock Option (Right to Buy)A Award	Principal Fin'l & Accounting	AAward	+97.5K sh	—	—	97,534
2021-04-06	Myovant Sciences Ltd.S Sale	Principal Fin'l & Accounting	SSale	−11.1K sh	$18.63	−$206K	152,390
2021-02-16	Myovant Sciences Ltd.Stock Option (Right to Buy)M Exercise/Conversion	Principal Fin'l & Accounting	MExercise/Conversion	−750 sh	—	—	181,744
2021-02-16	Myovant Sciences Ltd.S Sale	Principal Fin'l & Accounting	SSale	−750 sh	$21.40	−$16K	163,470
2021-02-16	Myovant Sciences Ltd.M Exercise/Conversion	Principal Fin'l & Accounting	MExercise/Conversion	+750 sh	$5.11	+$3,832.5	164,220
2021-01-28	Myovant Sciences Ltd.Stock Option (Right to Buy)M Exercise/Conversion	Principal Fin'l & Accounting	MExercise/Conversion	−300 sh	—	—	182,494
2021-01-28	Myovant Sciences Ltd.S Sale	Principal Fin'l & Accounting	SSale	−300 sh	$24.00	−$7,200	163,470
2021-01-28	Myovant Sciences Ltd.M Exercise/Conversion	Principal Fin'l & Accounting	MExercise/Conversion	+300 sh	$5.11	+$1,533	163,770
2021-01-15	Myovant Sciences Ltd.Stock Option (Right to Buy)M Exercise/Conversion	Principal Fin'l & Accounting	MExercise/Conversion	−750 sh	—	—	182,794
2021-01-15	Myovant Sciences Ltd.S Sale	Principal Fin'l & Accounting	SSale	−750 sh	$21.50	−$16.1K	163,470
2021-01-15	Myovant Sciences Ltd.M Exercise/Conversion	Principal Fin'l & Accounting	MExercise/Conversion	+750 sh	$5.11	+$3,832.5	164,220
2020-12-28	Myovant Sciences Ltd.Stock Option (Right to Buy)M Exercise/Conversion	Principal Fin'l & Accounting	MExercise/Conversion	−11.8K sh	—	—	183,544
2020-12-28	Myovant Sciences Ltd.S Sale	Principal Fin'l & Accounting	SSale	−11.8K sh	$30.00	−$354K	163,470
2020-12-28	Myovant Sciences Ltd.M Exercise/Conversion	Principal Fin'l & Accounting	MExercise/Conversion	+11.8K sh	$5.11	+$60.3K	175,270
2020-12-15	Myovant Sciences Ltd.S Sale	Principal Fin'l & Accounting	SSale	−670 sh	$24.45	−$16.4K	163,470
2020-12-15	Myovant Sciences Ltd.S Sale	Principal Fin'l & Accounting	SSale	−380 sh	$23.63	−$8,980.198	164,140
2020-12-15	Myovant Sciences Ltd.M Exercise/Conversion	Principal Fin'l & Accounting	MExercise/Conversion	+1,050 sh	$5.11	+$5,365.5	164,520
2020-12-15	Myovant Sciences Ltd.Stock Option (Right to Buy)M Exercise/Conversion	Principal Fin'l & Accounting	MExercise/Conversion	−1,050 sh	—	—	195,344
2020-11-30	Myovant Sciences Ltd.Stock Option (Right to Buy)M Exercise/Conversion	Principal Fin'l & Accounting	MExercise/Conversion	−1,500 sh	—	—	196,394
2020-11-30	Myovant Sciences Ltd.S Sale	Principal Fin'l & Accounting	SSale	−1,500 sh	$24.00	−$36K	163,470
2020-11-30	Myovant Sciences Ltd.M Exercise/Conversion	Principal Fin'l & Accounting	MExercise/Conversion	+1,500 sh	$5.11	+$7,665	164,970
2020-11-17	Myovant Sciences Ltd.Stock Option (Right to Buy)M Exercise/Conversion	Principal Fin'l & Accounting	MExercise/Conversion	−750 sh	—	—	197,894
2020-11-17	Myovant Sciences Ltd.M Exercise/Conversion	Principal Fin'l & Accounting	MExercise/Conversion	+750 sh	$5.11	+$3,832.5	164,220
2020-11-17	Myovant Sciences Ltd.S Sale	Principal Fin'l & Accounting	SSale	−750 sh	$20.00	−$15K	163,470
2020-11-13	Myovant Sciences Ltd.Stock Option (Right to Buy)M Exercise/Conversion	Principal Fin'l & Accounting	MExercise/Conversion	−750 sh	—	—	198,644
2020-11-13	Myovant Sciences Ltd.S Sale	Principal Fin'l & Accounting	SSale	−750 sh	$20.00	−$15K	163,470

Recent filings

Accepted (ET)
May 214
KARBE FRANK0001193125-26-234564
SEC(opens sec.gov)
Jan 74
KARBE FRANK0001276700-26-000002
SEC(opens sec.gov)
Dec 124
KARBE FRANK0001610618-25-000102
SEC(opens sec.gov)
Jun 54
KARBE FRANK0000950170-25-082458
SEC(opens sec.gov)
Feb 264
KARBE FRANK0001610618-25-000012
SEC(opens sec.gov)
Dec 164
KARBE FRANK0000950170-24-136391
SEC(opens sec.gov)
May 314
KARBE FRANK0000950170-24-067365
SEC(opens sec.gov)
May 244
KARBE FRANK0000950170-24-064820
SEC(opens sec.gov)
Dec 204
KARBE FRANK0000950170-23-071939
SEC(opens sec.gov)
Jul 314
KARBE FRANK0000950170-23-035680
SEC(opens sec.gov)
May 304
KARBE FRANK0001209191-23-033007
SEC(opens sec.gov)
Apr 124
KARBE FRANK0000899243-23-011189
SEC(opens sec.gov)
Sep 154
KARBE FRANK0000899243-22-031206
SEC(opens sec.gov)
Jul 74
KARBE FRANK0000899243-22-025715
SEC(opens sec.gov)

Companies

Address

C/O PHATHOM PHARMACEUTICALS, INC. 100 CAMPUS DRIVE, SUITE 102

FLORHAM PARK, NJ, 07932